基于血管造影的生理学评估指导冠状动脉血运重建
FAST III是一项国际、开放标签、随机、非劣效性试验,在欧洲37个中心纳入直径狭窄30%~80%的中间冠状动脉病变患者(慢性或急性冠脉综合征),1:1随机接受vFFR指导或FFR指导的血运重建。vFFR组1116例、FFR组1095例纳入主要终点分析。1年时主要复合终点(全因死亡、任何心肌梗死或任何血运重建)在vFFR组80例(Kaplan-Meier估计7.5%)、FFR组79例(7.5%),风险差-0.02个百分点(95%CI -2.25~2.21),非劣效性P=0.004。两组严重不良事件发生率似乎相似。
要点
- 中间冠状动脉病变(直径狭窄30%~80%)患者中,vFFR指导血运重建1年主要复合终点7.5%,FFR指导组7.5%,风险差-0.02个百分点(95%CI -2.25~2.21),达到非劣效(非劣效界值3.0个百分点,P=0.004)。
- vFFR由三维定量冠状动脉造影推导,无需压力导丝或充血剂,可作为FFR指导中间病变血运重建的替代策略。
- 研究纳入慢性或急性冠脉综合征患者,18.7%为急性冠脉综合征,26.6%合并糖尿病,平均年龄67岁,女性占24.3%。
- 两组严重不良事件发生率似乎相似。
适用人群与场景
- 欧洲37个中心、直径狭窄30%~80%的中间冠状动脉病变患者,表现为慢性或急性冠脉综合征,随机接受vFFR或FFR指导的中间冠状动脉病变血运重建。
诊断标准与关键阈值
- 中间冠状动脉病变定义为直径狭窄30%~80%。
研究设计与关键结果
- 国际、开放标签、随机、非劣效性试验,在欧洲37个中心纳入中间冠状动脉病变(直径狭窄30%~80%)患者,1:1随机接受vFFR指导或FFR指导血运重建。
- 主要终点为1年全因死亡、任何心肌梗死或任何血运重建的复合终点,非劣效界值3.0个百分点。
- 主要终点评估vFFR组1116例、FFR组1095例;平均年龄67岁,女性24.3%,急性冠脉综合征18.7%,糖尿病26.6%。
- 1年主要终点事件:vFFR组80例(Kaplan-Meier估计7.5%)vs FFR组79例(Kaplan-Meier估计7.5%),风险差-0.02个百分点(95%CI -2.25~2.21),非劣效性P=0.004。
- 两组严重不良事件发生率似乎相似。
证据类型、等级与局限
- 证据类型:国际、开放标签、随机、非劣效性试验(FAST III,NCT04931771)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于直径狭窄30%~80%的中间冠状动脉病变患者,vFFR指导的血运重建在1年死亡、心肌梗死或再次血运重建复合终点上不劣于FFR指导,vFFR无需压力导丝或充血剂。
指南或共识出处
- FAST III试验(ClinicalTrials.gov NCT04931771),由Pie Medical Imaging和Siemens Healthineers资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Current society guidelines recommend physiological assessment of intermediate coronary lesions to guide revascularization. Data regarding revascularization guided by vessel fractional flow reserve (vFFR), derived from three-dimensional quantitative coronary angiography without the need for a pressure wire or hyperemic agent, as compared with pressure-wire-based fractional flow reserve (FFR), are lacking.
METHODS: We conducted an international, open-label, randomized, noninferiority trial at 37 sites in Europe. Patients with intermediate coronary-artery lesions (diameter stenosis of 30 to 80%) who presented with chronic or acute coronary syndromes were randomly assigned in a 1:1 ratio to undergo either vFFR-guided or FFR-guided revascularization of the intermediate coronary-artery lesions. The primary end point was a composite of death from any cause, any myocardial infarction, or any revascularization at 1 year. The noninferiority margin was 3.0 percentage points.
RESULTS: The primary end point was assessed in 1116 patients in the vFFR group and 1095 in the FFR group. The mean age of the patients was 67 years, 24.3% were women, 18.7% presented with an acute coronary syndrome, and 26.6% had diabetes mellitus. At 1 year, a primary end-point event had occurred in 80 patients (Kaplan-Meier estimate, 7.5%) in the vFFR group and in 79 patients (Kaplan-Meier estimate, 7.5%) in the FFR group (risk difference, -0.02 percentage points; 95% confidence interval, -2.25 to 2.21; P = 0.004 for noninferiority). The incidence of serious adverse events appeared to be similar in the two groups.
CONCLUSIONS: Among patients with intermediate coronary lesions, vFFR-guided revascularization was noninferior to FFR-guided revascularization with respect to a composite of death, myocardial infarction, or revascularization at 1 year. (Funded by Pie Medical Imaging and Siemens Healthineers; FAST III ClinicalTrials.gov number, NCT04931771.).
参考来源
- Daemen J, van der Eijk JA, Barbierato M, et al. Angiography-Based Physiology to Guide Coronary Revascularization. N Engl J Med. 2026. PMID: 41910382. doi:10.1056/NEJMoa2601841
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。